Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease

Robbert Spaapen, Tuna Mutis

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions can induce durable remission in patients with haematological malignancies through a graft-versus-tumour (GvT) effect. In human leukocyte antigen (HLA)-matched settings, this powerful immunotherapeutic effect is predominantly mediated by donor T cells directed at the recipient's minor histocompatibility antigens (mHags) presented on malignant cells. The mHags are short peptides excised from polymorphic regions of intracellular proteins, and are presented by HLA molecules to donor T cells. Several ubiquitously expressed mHags are involved not only in GvT but also in graft-versus-host disease (GvHD). However, a specific set of mHags is expressed exclusively by haematopoietic cells and their malignant counterparts. Targeting these haematopoietic mHags is an attractive strategy to induce specific GvT effects without increasing the risk of GvHD. This chapter will summarize the current efforts to identify therapeutically relevant haematopoietic mHags, and outline the strategies to apply mHag-based cellular immunotherapy to treat recurrent malignancies after allo-SCT.

Original languageEnglish
Pages (from-to)543-557
Number of pages15
JournalBest Practice and Research: Clinical Haematology
Volume21
Issue number3
DOIs
Publication statusPublished - 1 Sep 2008

Cite this

@article{2f90a5112b9f4b948ab5f333a6e6de98,
title = "Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease",
abstract = "Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions can induce durable remission in patients with haematological malignancies through a graft-versus-tumour (GvT) effect. In human leukocyte antigen (HLA)-matched settings, this powerful immunotherapeutic effect is predominantly mediated by donor T cells directed at the recipient's minor histocompatibility antigens (mHags) presented on malignant cells. The mHags are short peptides excised from polymorphic regions of intracellular proteins, and are presented by HLA molecules to donor T cells. Several ubiquitously expressed mHags are involved not only in GvT but also in graft-versus-host disease (GvHD). However, a specific set of mHags is expressed exclusively by haematopoietic cells and their malignant counterparts. Targeting these haematopoietic mHags is an attractive strategy to induce specific GvT effects without increasing the risk of GvHD. This chapter will summarize the current efforts to identify therapeutically relevant haematopoietic mHags, and outline the strategies to apply mHag-based cellular immunotherapy to treat recurrent malignancies after allo-SCT.",
keywords = "adoptive immunotherapy, dendritic cell vaccination, graft-versus-host disease, graft-versus-tumour effect, minor histocompatibility antigens",
author = "Robbert Spaapen and Tuna Mutis",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.beha.2008.06.001",
language = "English",
volume = "21",
pages = "543--557",
journal = "Best practice & research clinical haematology",
issn = "1521-6926",
publisher = "Bailliere Tindall Ltd",
number = "3",

}

Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease. / Spaapen, Robbert; Mutis, Tuna.

In: Best Practice and Research: Clinical Haematology, Vol. 21, No. 3, 01.09.2008, p. 543-557.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Targeting haematopoietic-specific minor histocompatibility antigens to distinguish graft-versus-tumour effects from graft-versus-host disease

AU - Spaapen, Robbert

AU - Mutis, Tuna

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions can induce durable remission in patients with haematological malignancies through a graft-versus-tumour (GvT) effect. In human leukocyte antigen (HLA)-matched settings, this powerful immunotherapeutic effect is predominantly mediated by donor T cells directed at the recipient's minor histocompatibility antigens (mHags) presented on malignant cells. The mHags are short peptides excised from polymorphic regions of intracellular proteins, and are presented by HLA molecules to donor T cells. Several ubiquitously expressed mHags are involved not only in GvT but also in graft-versus-host disease (GvHD). However, a specific set of mHags is expressed exclusively by haematopoietic cells and their malignant counterparts. Targeting these haematopoietic mHags is an attractive strategy to induce specific GvT effects without increasing the risk of GvHD. This chapter will summarize the current efforts to identify therapeutically relevant haematopoietic mHags, and outline the strategies to apply mHag-based cellular immunotherapy to treat recurrent malignancies after allo-SCT.

AB - Allogeneic stem cell transplantation (allo-SCT) and donor lymphocyte infusions can induce durable remission in patients with haematological malignancies through a graft-versus-tumour (GvT) effect. In human leukocyte antigen (HLA)-matched settings, this powerful immunotherapeutic effect is predominantly mediated by donor T cells directed at the recipient's minor histocompatibility antigens (mHags) presented on malignant cells. The mHags are short peptides excised from polymorphic regions of intracellular proteins, and are presented by HLA molecules to donor T cells. Several ubiquitously expressed mHags are involved not only in GvT but also in graft-versus-host disease (GvHD). However, a specific set of mHags is expressed exclusively by haematopoietic cells and their malignant counterparts. Targeting these haematopoietic mHags is an attractive strategy to induce specific GvT effects without increasing the risk of GvHD. This chapter will summarize the current efforts to identify therapeutically relevant haematopoietic mHags, and outline the strategies to apply mHag-based cellular immunotherapy to treat recurrent malignancies after allo-SCT.

KW - adoptive immunotherapy

KW - dendritic cell vaccination

KW - graft-versus-host disease

KW - graft-versus-tumour effect

KW - minor histocompatibility antigens

UR - http://www.scopus.com/inward/record.url?scp=51549093590&partnerID=8YFLogxK

U2 - 10.1016/j.beha.2008.06.001

DO - 10.1016/j.beha.2008.06.001

M3 - Review article

VL - 21

SP - 543

EP - 557

JO - Best practice & research clinical haematology

JF - Best practice & research clinical haematology

SN - 1521-6926

IS - 3

ER -